Literature DB >> 767114

Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma.

I Könyves, B Nordenskjöld, G P Forshell, A de Schryver, H Westerberg-Larsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 767114     DOI： 10.1016/0014-2964(75)90082-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  10 in total

1.  Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.

Authors:  M M Oppitz; E Musch; M Malek; H P Rüb; G E von Unruh; U Loos; B Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  The clinical pharmacology of chlorambucil and prednimustine.

Authors:  D R Newell; A H Calvert; K R Harrap; T J McElwain
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

4.  Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Authors:  H Ehrsson; I Wallin; S O Nilsson; B Johansson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.

Authors:  H Samonigg; H Stöger; A K Kasparek; M Schmid; J Dusleag; K Pfeiffer; M Smola; P Steindorfer; P Lechner
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.

Authors:  H T Mouridsen; E Boesen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

7.  Disposition of orally administered 14C-prednimustine in cancer patients.

Authors:  R C Gaver; G Deeb; K A Pittman; B F Issell; A Mittelman; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

Authors:  D R Newell; A H Calvert; K R Harrap; T J McElwain
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

10.  Prednimustine in adult acute myeloid leukaemia.

Authors:  L Brandt; I Könyves
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.